A new proof-of-concept study published in the May issue of The Journal of Nuclear Medicine has demonstrated that molecular imaging can be used for identifying early response to 177Lu-DOTATATE treatment in neuroendocrine tumor patients. Monitoring the DNA damage response with molecular imaging in the early days after the radionuclide injection could allow physicians to determine the therapeutic outcome and adapt the therapy regimen accordingly.
- Oahu marine protected areas offer limited protection of coral reef herbivorous fishes
- Picture books can boost physical activity for youth with autism
- Atherosclerosis can accelerate the development of clonal hematopoiesis, study finds
- Deep brain stimulation and exercise restore movement in ataxia
- ‘Explicit instruction’ provides dramatic benefits in learning to read